Any current/future new fundraising through debt or equity?

The company plans to fund the Khopoli plant expansion primarily through external loans, with bank sanctions already obtained for the funding. There is no mention of any planned equity fundraising related to this expansion or otherwise. For non-core assets like land in Bhiwandi, monetization might be considered at the right time, but the current focus remains on pharma operations and the capex projects. The company aims to sustain growth through internal accruals and bank funding rather than new equity issuance.

Any current/future capex/capital investment/strategic investment?

Khopoli Plant Expansion: - Estimated capital expenditure: More than INR 100 crores. - Funding: Mostly through external bank loans; sanctions have been received. - Timeline: Plant construction to take about two years; production expected to start from March 2025 onwards. - Capacity details to be consolidated and shared later. Ethiopia Plant: - Current operations ramping up after initial struggles. - Plans to increase supply and possibly export within African countries. - Government support with tax benefits: Four years of income tax exemption starting July 2021 till July 2025. N

Future growth expectations in sales/revenue/volumes?

Company expects robust growth in Ethiopia business in FY 2023-24 as government has agreed in principle to provide foreign exchange to support imports, enabling full utilization of Cephalosporin plant capacity. Overall sales growth of 30% to 35% year-on-year was reported, with export commissions rising in line with sales. Indian pharmaceutical market projected to see double-digit growth, driven by potential increases in government healthcare spending. Injectable business expected to grow with plans for increased capacity at Khopoli plant; running multiple shifts planned to meet growing demand.

Future growth expectations in earnings/operating earnings/profits/EPS?

Kilitch Drugs India Limited expects continued robust growth in earnings and profits driven by multiple factors. Domestic pharma market anticipated to grow at double-digit rates, supported by increased government healthcare spend. Ethiopian manufacturing unit poised for a robust ramp-up, with government backing and forex allocation improving operational capacity. EBITDA margins have shown improvement (from 14.8% to 18.8%) and management aims for further margin enhancements in coming quarters. New Khopoli plant expansion (> INR 100 crores capex) will augment capacity, supporting growth, especial

Current/ Expected Orderbook/ Pending Orders?

No specific numeric details on the current or expected order book were mentioned in the transcript. The management expressed confidence in demand growth, citing an 8% to 12% year-on-year growth trend in the pharma market. The additional capacity at the Khopoli plant was conceptualized anticipating increased demand and possible capacity shortfalls. While no formal offtake agreements for the new capacity were signed, the company expects existing customers to create demand based on market trends. In Ethiopia, government tenders have been delayed due to forex issues but are expected to be addresse

Kilitch Drugs (India) LtdQ4 FY23Pharmaceuticals & Biotechnology

Kilitch Drugs (India) Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹201.32P/E: 23.5Market Cap: ₹705 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Company expects robust growth in Ethiopia business in FY 2023-24 as government has agreed in principle to provide foreign exchange to support imports, enabling full utilization of Cephalosporin plant capacity.
Overall sales growth of 30% to 35% year-on-year was reported, with export commissions rising in line with sales.
Indian pharmaceutical market projected to see double-digit growth, driven by potential increases in government healthcare spending.
Injectable business expected to grow with plans for increased capacity at Khopoli plant; running multiple shifts planned to meet growing demand.
Exports from the Ethiopian plant to other African countries (Sudan, Uganda, Kenya, Tanzania, Nigeria) anticipated within 1-2 years after product registration and approvals.
Capacity expansions and government contracts are expected to drive increased production volumes and revenues.
Continued focus on contract manufacturing and exploring opportunities to monetize non-core land assets for capital deployment.

Margin guidance

Category 2

Kilitch Drugs India Limited expects continued robust growth in earnings and profits driven by multiple factors.
Domestic pharma market anticipated to grow at double-digit rates, supported by increased government healthcare spend.
Ethiopian manufacturing unit poised for a robust ramp-up, with government backing and forex allocation improving operational capacity.
EBITDA margins have shown improvement (from 14.8% to 18.8%) and management aims for further margin enhancements in coming quarters.
New Khopoli plant expansion (> INR 100 crores capex) will augment capacity, supporting growth, especially in contract manufacturing.
EPS grew significantly to INR 10.09 in FY23 from INR 6.76, with management optimistic on sustaining this growth trajectory.
Overall, growth will be fueled by expansion in both domestic and export markets, capacity ramp-ups, and operational efficiencies.

See what Kilitch Drugs (India) Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company plans to fund the Khopoli plant expansion primarily through external loans, with bank sanctions already obtained for the funding.
There is no mention of any planned equity fundraising related to this expansion or otherwise.
For non-core assets like land in Bhiwandi, monetization might be considered at the right time, but the current focus remains on pharma operations and the capex projects.
The company aims to sustain growth through internal accruals and bank funding rather than new equity issuance.

Order book

No specific numeric details on the current or expected order book were mentioned in the transcript.
The management expressed confidence in demand growth, citing an 8% to 12% year-on-year growth trend in the pharma market.
The additional capacity at the Khopoli plant was conceptualized anticipating increased demand and possible capacity shortfalls.
While no formal offtake agreements for the new capacity were signed, the company expects existing customers to create demand based on market trends.
In Ethiopia, government tenders have been delayed due to forex issues but are expected to be addressed soon, potentially boosting orders.
The private market currently accounts for Ethiopian sales, with supply to government expected to start after forex support.
Overall, management is optimistic about a robust sales ramp-up with capacity expansions supporting growth.

See what Kilitch Drugs (India) Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Khopoli Plant Expansion:
- Estimated capital expenditure: More than INR 100 crores.
- Funding: Mostly through external bank loans; sanctions have been received.
- Timeline: Plant construction to take about two years; production expected to start from March 2025 onwards.
- Capacity details to be consolidated and shared later.
Ethiopia Plant:
- Current operations ramping up after initial struggles.
- Plans to increase supply and possibly export within African countries.
- Government support with tax benefits: Four years of income tax exemption starting July 2021 till July 2025.
Non-core assets:
- Land in Bhiwandi may be monetized at the right opportunity but focus remains on pharma-related capex.
Overall, strategic investments focus on expanding manufacturing capacity to meet growing demand in both domestic and export markets.

Track Kilitch Drugs (India) Ltd — get its next earnings analysis in your feed

How does Kilitch Drugs (India) Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisKilitch Drugs (India) Ltd

Rev 2Mar 2

See where Kilitch Drugs (India) Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Kilitch Drugs (India) Ltd rank in Pharmaceuticals & Biotechnology?

Compare Kilitch Drugs (India) Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Kilitch Drugs (India) Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Kilitch Drugs (India) Ltd Q4 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Kilitch Drugs (India) Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Kilitch Drugs (India) Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season